



Article

Age-Related sncRNAs in Human Hippocampal Tissue Samples: Focusing on Deregulated miRNAs

Ainhoa Alberro ^{1,2}, Rocío Del Carmen Bravo-Miana ^{1,2}, Saioa GS Iñiguez ¹, Andrea Iribarren-López ^{1,2},
Marta Arroyo-Izaga ³, Ander Matheu ^{4,5,6}, Maider Muñoz-Culla ^{1,2,7,*} and David Otaegui ^{1,2,*}

- ¹ Neuroimmunology Group, Neuroscience Area, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain; ainhoa.alberrogaritano@bio-gipuzkoa.eus (A.A.); rociodelcarmen.bravomiana@bio-gipuzkoa.eus (R.D.C.B.-M.); saioa.garcia-serranoiguez@bio-gipuzkoa.eus (S.G.S.I.); andrea.iribarrenlopez@bio-gipuzkoa.eus (A.I.-L.)
 - ² Neurodegenerative Diseases Research Area of CIBER (CIBERNED), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain
 - ³ BIOMiCs Research Group, Lascaray Research Center, University of the Basque Country (UPV/EHU), Bioaraba, 01006 Vitoria-Gasteiz, Spain; marta.arroyo@ehu.eus
 - ⁴ Cellular Oncology Group, Oncology Area, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain; ander.matheufernandez@bio-gipuzkoa.eus
 - ⁵ IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Spain
 - ⁶ Frailty and Healthy Ageing Research Area of CIBER (CIBERfes), Carlos III Health Institute (ISCIII), 28029 Madrid, Spain
 - ⁷ Department of Basic Psychological Processes and Their Development, University of the Basque Country (UPV/EHU), 20018 San Sebastián, Spain
- * Correspondence: maider.munoz@ehu.eus (M.M.-C.); david.otaegui@bio-gipuzkoa.eus (D.O.)
† These authors contributed equally to this work.



Citation: Alberro, A.; Bravo-Miana, R.D.C.; GS Iñiguez, S.; Iribarren-López, A.; Arroyo-Izaga, M.; Matheu, A.; Muñoz-Culla, M.; Otaegui, D. Age-Related sncRNAs in Human Hippocampal Tissue Samples: Focusing on Deregulated miRNAs. *Int. J. Mol. Sci.* **2024**, *25*, 12872. <https://doi.org/10.3390/ijms252312872>

Academic Editor: Alfredo Ciccodicola

Received: 9 October 2024

Revised: 21 November 2024

Accepted: 25 November 2024

Published: 29 November 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Small non-coding RNAs (sncRNAs), particularly microRNAs (miRNAs), play an important role in transcriptome regulation by binding to mRNAs and post-transcriptionally inhibiting protein production. This regulation occurs in both physiological and pathological conditions, where the expression of many miRNAs is altered. Previous reports by our group and others have demonstrated that miRNA expression is also altered during aging. However, most studies have analyzed human peripheral blood samples or brain samples from animal models, leaving a gap in knowledge regarding miRNA expression in the human brain. In this work, we analyzed the expression of sncRNAs from coronal sections of human hippocampal samples, a tissue with a high vulnerability to deleterious conditions such as aging. Samples from young (n = 5, 27–49 years old), old (n = 8, 58–88 years old), and centenarian (n = 3, 97, 99, and 100 years old) individuals were included. Our results reveal that sncRNAs, particularly miRNAs, are differentially expressed (DE) in the human hippocampus with aging. Besides, miRNA-mediated regulatory networks revealed significant interactions with mRNAs deregulated in the same hippocampal samples. Surprisingly, 80% of DE mRNA in the centenarian vs. old comparison are regulated by hsa-miR-192-5p and hsa-miR-3135b. Additionally, validated hsa-miR-6826-5p, hsa-let-7b-3p, hsa-miR-7846, and hsa-miR-451a emerged as promising miRNAs that are deregulated with aging and should be further investigated.

Keywords: small non-coding RNA; miRNA; brain; hippocampus; aging; longevity; transcriptome regulation; centenarians

1. Introduction

Aging is a complex and multifactorial process characterized by a progressive decline in physiological functions and an increased vulnerability to diseases, ultimately leading to death [1–3]. Understanding the molecular mechanisms that drive aging is critical for developing strategies to promote healthy aging and treat age-associated diseases. In this field, one of the emerging research areas is the study of transcriptome regulation [4]. Small

non-coding RNAs (sncRNAs), particularly microRNAs (miRNAs), play significant roles in regulating gene expression and have been previously associated with aging [5–9].

miRNAs are typically 20–24 nucleotides in length and exert their regulatory functions by binding to complementary sequences on target RNAs, including messenger RNAs (mRNAs), introns, and 3' untranslated regions (UTRs), resulting in mRNA degradation and, at the post-transcriptional level, inhibiting the protein production [10–12]. Since their discovery in the early 1990s, miRNAs have been found to be implicated in several biological processes, including development, differentiation, cell proliferation, stress responses, and apoptosis, and they have also been shown to be implicated in the aging and longevity processes [11,13]. miRNAs can regulate specific target genes involved in fundamental cellular processes, and their deregulation could be a consequence of age-related cellular stress and senescence, representing a possible protective response or perhaps a cause [14–16]. Understanding the complex interactions between miRNAs and their target genes will be essential to unlock their full potential in aging and longevity.

In this context, previous reports by our group and others found that miRNA expression is also altered by physiological aging [5,17,18]. However, most studies analyzed human peripheral blood samples [5,18,19] or other cell models [20], as well as brain samples from animal models [19,21,22]. This leaves a significant gap in our knowledge of miRNA expression in the human brain. In this work, we evaluated miRNA expression in the human hippocampus—a biologically complex region associated with learning and memory formation and storage—from young, old, and centenarian samples as a model of healthy aging.

2. Results

2.1. Differentially Expressed miRNAs in Human Hippocampal Tissue with Age

A microarray analysis was performed to study the sncRNAs differentially expressed in hippocampal tissue samples ($n = 16$, Table 1). The results obtained from the differential expression analysis (fold change (FC) $> |2|$ and p -value < 0.05) identified 10 differentially expressed (DE) sncRNAs (9 DE miRNAs) in old vs. young samples (Figure 1A), 11 DE sncRNAs (10 DE miRNAs) in centenarian vs. old (Figure 1B), and 20 DE sncRNAs (18 DE miRNAs) in centenarian vs. young (Figure 1C). Detailed information, including transcript ID, accession number, FC, and p -value obtained for each DE feature, are shown in Table S1. Specifically, we found that among the 41 DE sncRNAs, 24 sncRNAs were upregulated in old vs. young (3 sncRNAs), in centenarian vs. old (8 sncRNAs), and in centenarian vs. young individuals (13 sncRNAs). Conversely, 17 sncRNAs were downregulated, with 7, 3, and 7 showing a decreased expression, respectively, in each comparison. Remarkably, a greater number of miRNAs were altered in centenarians compared to young individuals than in old relative to young subjects. In addition, 90% of the DE sncRNAs were miRNAs, and only one small nucleolar RNA (snoRNA), snR38A, was downregulated in the old vs. young group. A Venn diagram of the DE sncRNAs across the three comparisons showed one common miRNA (hsa-miR-4314) between centenarian vs. old and centenarian vs. young comparisons and six miRNAs between old vs. young and centenarian vs. young (Figure 1D).

Table 1. Information about the post-mortem brain donors.

Discovery Cohort		
Age Range (Years)	Sex (Female/Male)	n
27–49	1/4	5
58–88	1/7	8
97–100	2/1	3

Table 1. Cont.

Validation Cohort		
Age Range (Years)	Sex (Female/Male)	n
20–50	12/65	77
65–82	9/28	37
92–96	3/1	4




Figure 1. Statistically significant sncRNAs from post-mortem hippocampal RNA samples. Unsupervised hierarchical clustering of the log2 expression value of the DE sncRNA obtained between (A) old vs. young, (B) centenarian vs. old, and (C) centenarian vs. young. Of note, using a p -value < 0.05 and $FC \geq |2|$, DE sncRNAs revealed are principally miRNAs. (D) Venn diagram showing DE sncRNAs that overlap among the comparisons. (E) Twelve mature miRNAs that present a significant positive (11 miRNAs) and negative (1 miRNA) correlation with age using a p -value < 0.01 and $r > |0.6|$ as the cut-off. (F) Venn diagram of the mature miRNAs revealed by DE and correlation analyses showing overlapping. DE: differentially expressed.

Additionally, a correlation analysis was conducted between sncRNA expression and age to identify further relevant features. sncRNAs that present a positive or negative Pearson correlation coefficient ($r > |0.6|$) and a p -value < 0.01 are shown in Table S2. This analysis revealed 12 mature miRNAs that gradually increase or decrease with age (Figure 1E). Among these, six mature miRNAs were identified as being significant in both the differential expression and correlation analyses (Figure 1F).

2.2. miRNA-Mediated Regulatory Networks Revealed Significant Interactions with mRNAs Analyzed in the Same Hippocampal Samples

Taking advantage of the available data, we built interaction networks to conduct a comprehensive analysis of the transcriptional mRNA regulation mediated by DE miRNAs in the context of the human hippocampus. Briefly, the putative mRNA targets of the DE miRNAs were obtained from the miRTarBase database. Since the DE mRNA data of the same brain donors had been previously published (see [17], Saez-Antoñanzas et al., 2024), only interactions between DE mRNA targets regulated by the DE miRNAs in the same sample were considered in the networks. Finally, interactions exhibiting opposite regulation (with an $FC > |1.2|$) were plotted (Figure S1A), i.e., those in which if the microRNA was upregulated, its mRNA target was downregulated, or vice versa.


For the old vs. young comparison, this analysis identified 2646 in silico potential interactions in the miRTarBase database, which were reduced to 1095 experimentally validated potential interactions and, finally, to 17 mRNAs showing an opposite regulation ($FC > |1.2|$) with six miRNAs in the studied samples (Figures 2A and S1B). In the centenarian vs. old comparison, a total of 4664 in silico potential interactions were identified. Of these, 2151 were experimentally validated potential interactions, and we found 47 interactions with opposite regulation, involving 44 mRNAs and six miRNAs (Figures 2B and S1C). In the centenarian vs. young comparison, there were 6044 in silico interactions, with 2598 experimentally validated in the database, and we reported 39 interactions with opposite regulation (which involved 36 mRNAs and 12 miRNAs) in our samples (Figures 2C and S1D). On the other hand, the list of miRNAs identified through the correlation analysis was used for the same analysis, revealing 4706 in silico potential interactions, 31 experimentally validated potential interactions, and, finally, 18 miRNA–mRNA interactions with opposite regulation found in the studied samples (17 mRNAs and 10 miRNAs). Of note, DE miRNAs and DE mRNA target nodes were colored based on the FC (Figure 2A–C) or the positive/negative correlation trend with age (Figure 2D). Changes in miRNA expression were linked to alterations in target mRNA levels. Surprisingly, the highest number of significant DE mRNA–miRNA interactions were observed in the comparison between centenarians and old individuals. Furthermore, most interactions are concentrated in only two miRNAs (hsa-miR-192-5p and hsa-miR-3135b). Finally, the mentioned 17, 44, 36, and 17 age-related mRNAs regulated by miRNAs in each comparison were used for a Gene Ontology (GO) analysis. However, no relevant GO information could be obtained from the shortlists of targeted mRNA.

2.3. hsa-miR-6826-5p, hsa-let-7b-3p, hsa-miR-7846-3p, and hsa-miR-451a Significantly Correlated with Age

After the analysis, six candidates were selected from those identified through differential expression and correlation analysis and subsequently validated in an independent cohort of 118 hippocampal RNA samples. These exhibited an $FC > |2.5|$ and/or a Pearson correlation coefficient $r > |0.6|$ and are shown in Table S3, along with the type(s) of analysis through which they were identified.


hsa-miR-6826-5p was significantly upregulated in old compared to young individuals, with a trend to a higher expression in centenarian vs. young individuals (Figure 3A). Similarly, hsa-let-7b-3p was significantly upregulated in old compared to young donors, with a trend towards even higher expression in centenarians (Figure 3C). Other miRNA candidates did not show significant differences under the studied conditions. On the other hand, the correlation analysis in the validation cohort showed that hsa-miR-6826-5p, hsa-let-7b-3p, and hsa-miR-7846 have a significant positive correlation with age (Figure 3A,C,F) while hsa-miR-451a displayed a significant negative correlation with age (Figure 3E). However, hsa-miR-4441 and hsa-miR-1825 did not show significant age-related correlations (Figure 3B,D).

A DE analysis: Old vs young




9 DE miRNAs & 2646 miRTarBase target genes
19 DE miRNA-mRNA opposite interactions

B DE analysis: Centenarian vs old




10 DE miRNAs & 4664 miRTarBase target genes
47 DE miRNA-mRNA opposite interactions

C DE analysis: Centenarian vs young



18 DE miRNAs & 6044 miRTarBase target genes
39 DE miRNA-mRNA opposite interactions

D Correlation analysis



12 DE miRNAs & 4076 miRTarBase target genes
18 DE miRNA-mRNA opposite interactions

Figure 2. miRNA–mRNA interaction networks. miRNA and target gene networks comparing (A) old vs. young, (B) centenarian vs. old, and (C) centenarian vs. young groups of samples, and considering the (D) correlation analysis. Networks were built using experimentally validated miRNA–mRNA interactions from the miRTarBase database and published transcriptomic data from the same post-mortem hippocampal tissue samples. miRNAs and target genes are color-coded based on FC (A–C) or correlation with age (D).




Figure 3. RT-qPCR validation of miRNA candidates. The miRNA candidates were validated by RT-qPCR in a second cohort of hippocampal RNA samples ($n = 118$). A comparative analysis between age groups and a Pearson correlation analysis with age were conducted. A significant increase in the (A) hsa-miR-6826-5p and (C) hsa-let-7b-3p expression in old when compared to young samples was observed (** $p < 0.01$ and * $p < 0.05$, respectively; ordinary one-way ANOVA test, Tukey's post hot test). Both hsa-miR-6826-5p and hsa-let-7b-3p expression showed a statistically significant positive correlation with age. (E) hsa-miR-451a and (F) hsa-miR-7846-3p did not show significant differences between groups. In contrast, a significant negative correlation between age and hsa-miR-451a expression and a positive correlation between age and hsa-miR-7846-3p expression were found. Neither (B) hsa-miR-4441 nor (D) hsa-miR-1825 expression levels showed significant differences between the groups, and no correlation with age was found. Data are expressed as the median \pm range of ΔCq from young ($n = 77$), old ($n = 37$), and centenarians ($n = 4$). ΔCq is the difference in Ct values between the miRNA candidate and the median of reference genes. To note, ΔCq values are inversely correlated with miRNA expression levels. A higher ΔCq means lower expression, and vice versa. ΔCq : delta quantification cycle. Those miRNAs whose correlation with age was statistically significant were marked in bold.

3. Discussion

The brain is a highly structured organ that contains billions of neurons, glial cells, and a vast vascular network. The hippocampus is a brain region vital for learning, memory, and emotional regulation, and it has been associated with age-related cognitive decline and the onset of dementia, presenting a pivotal role in the study of aging, longevity, frailty, and neurodegenerative diseases [23,24]. Our findings revealed that sncRNAs, and particularly miRNAs, are deregulated in the aged human hippocampus. To understand the potential effect of this deregulation and take advantage of the previously conducted transcriptomal analysis of the same samples (see [17], Saez-Antoñanzas et al., 2024), we built networks of the predicted interactions between the DE sncRNAs reported here and the DE mRNAs reported in the previous study. Interestingly, many of these DE mRNAs were oppositely targeted by more than one DE miRNA, such as SLC26A2, NFIC, TYRO3, and SPTLC3. It is noteworthy that four distinct DE miRNAs were predicted to interact with NFIC in the networks: Two miRNAs in centenarian vs. young and two miRNAs in centenarian vs. old. This gene encodes a DNA-binding protein that functions as a transcription factor. Its deregulation has been linked to central nervous system (CNS) diseases [25], like Alzheimer's disease [26], emphasizing the crucial role of the intricate network of transcriptome regulation. The network analysis also underlines the importance of hsa-miR-192-5p and hsa-miR-3135b as major regulators, being able to control 80% of DE mRNA identified between centenarians and old individuals. hsa-miR-192-5p was upregulated in centenarians in comparison to old individuals, and it has been related to neural function repair and the promotion of neural apoptosis in murine models [26]. Conversely, hsa-miR-3135b was downregulated in centenarians compared to old individuals, and it has been identified as a regulator of the REL/SOD2 pathway in a mouse model of ischemic cerebral infarction [27]. In addition, there are reports associating this microRNA with several other diseases, such as severe hypertension, heart failure, and diabetes [28–31]. However, neither hsa-miR-192-5p nor hsa-miR-3135b was previously related to aging or longevity. Considering that age-related changes driven by miRNAs are largely tissue-specific [32], the precise biological functions of these miRNAs within the brain, particularly in the hippocampus, should be further investigated.

On the other hand, with the validation cohort, our study highlights the significant positive correlation between hsa-let-7b-3p, hsa-miR-6826-5p, and hsa-miR-7846-3p with age. In contrast, hsa-miR-451a was negatively correlated with age. While hsa-let-7b-3p and hsa-miR-451a deregulation have been extensively reported in several tissues, hsa-miR-6826-5p and hsa-miR-7846-3p have been studied in only a few works.

hsa-let-7b-3p expression has been found in the brain [33,34] and specifically as a key regulator of multiple pathways in hippocampal samples of mesial temporal lobe epilepsy [34]. In addition, a study addressing chronological changes in the hippocampus revealed that hsa-let-7b increases in adults relative to fetal samples, suggesting an increase with age of this miRNA that is consistent with our results [35]. On the other hand, hsa-let-7b-3p was reported circulating in total plasma [36] as a predictive biomarker for amnesic mild cognitive impairment. Additionally, it was also identified circulating in extracellular vesicles (EVs) from cerebrospinal fluid (CSF) and serum "<http://microvesicles.org/> (accessed in 6 August 2024)" [37]. Our results further demonstrate that as hsa-let-7b-3p expression increases with age, its target Tetratricopeptide Repeat Domain 3 (TTC33)'s expression decreases. TTC33 plays a crucial role in several cellular processes, especially related to the ubiquitin-protein transferase activity, which is integral to protein quality control (PQC) and cellular homeostasis [38]. Although the implication of TTC33 in aging has not been directly explored, a decrease in its expression could disrupt these essential functions.

hsa-miR-451a has been found in brain tissues [39,40], as well as circulating free in CSF, plasma, serum, and salivary biofluids [41–44] and also in EV-enriched samples [45–47]. Its presence in CSF could be indicative of brain tissue damage after a severe traumatic injury [48]. Besides, its decreased CSF circulation was reported as a biomarker of both cognitive impairment and depressive symptoms in Alzheimer's disease patients [49] and

in the serum of frail compared to robust subjects [50]. Functionally, its overexpression plays a crucial role in accelerating neuronal differentiation *in vitro* and *in vivo* [51], and its presence in EVs demonstrates a prosenescence function in human dermal fibroblasts culture, showing a role in the age-related biological processes [52].

The literature on the role of hsa-miR-6826-5p and hsa-miR-7846 is limited, and none of the articles are related to brain physiopathology. Interestingly, our study reveals an age-related increase in hsa-miR-6826-5p expression, which coincides with a decrease in its target gene, *Cyp26b1*. This gene encodes a member of the cytochrome P450 superfamily and functions as a critical regulator of retinoic acid levels. *Cyp26b1* deficiency has been associated with impaired bone homeostasis and an unbalanced inflammatory response [53–55]. In addition, it has been proven that *Cyp26b1* knockdown causes reduced life expectancy and systemic inflammation in mice [56]. These findings raise the intriguing possibility that the observed changes in miR-6826-5p and *Cyp26b1* expression may contribute to brain aging processes through their influence on retinoic acid metabolism and related physiological pathways.

To our knowledge, this is the first work analyzing the small non-coding transcriptome in human hippocampal samples of old and centenarian individuals. We acknowledge that our work has some limitations regarding the sample analyzed. There is limited clinical information on the previous health status of the donors, which could increase the interindividual variability and include potential biological variables that might influence our results. Besides, taking into account the complexity of the hippocampus, we cannot establish whether the age-related changes in miRNA occur in the whole region or are specific to some areas of the hippocampus. Some authors report that a protein-coding gene expression gradient exists along the longitudinal axis [57] of the hippocampus, and this could also be the case for small non-coding RNAs, which should be explored in future research.

We acknowledge that our work has some limitations regarding the sample analyzed. There is limited clinical information on the previous health status of the donors, which could increase the interindividual variability. Besides, taking into account the complexity of the hippocampus.

4. Materials and Methods

4.1. Human Hippocampal Brain Samples

The discovery and validation cohort consisted of human hippocampal tissues obtained from forensic autopsy and provided by the BIOMICs group, which were part of the collection C.0000217 from the Institute of Health Carlos III Biobank register “<https://biobancos.isciii.es/ListadoColecciones.aspx>” (Bilbao, Spain) [17]. The sncRNAs characterization study was performed in coronal sections of hippocampal samples from 16 individuals, including young ($n = 5$, 27–49 years old), old ($n = 8$, 58–88 years old), and centenarian ($n = 3$, 97, 99, and 100 years old). This study was approved by the Clinical Research Ethics Committee of the Donostia University Hospital (protocol AMF-EGM-2016-01) and adhered to the tenets of the Declaration of Helsinki. Families authorized the use of these post-mortem human samples for research.

The validation cohort consisted of 118 hippocampal RNA samples composed of young (20–50 years old, $n = 77$), old (65–89 years old, $n = 37$), and centenarian (92–96 years old, $n = 4$) individuals. Table 1 shows the principal studied sample characteristics of discovery and validation cohorts.

4.2. RNA Extraction and Global sncRNA Analysis

Total RNA extraction was performed by Trizol (Life Technologies, Carlsbad, CA, USA). The sncRNAs have been profiled by Affymetrix arrays. Briefly, total RNA (200 ng) was labeled using the FlashTag HSR Biotin labeling kit (Genisphere LLC, Hatfield, Pennsylvania, PA, USA) and hybridized to the GeneChip miRNA 4.0 Array (Affymetrix, Santa Clara, CA, USA), which covers 2578, 2025 and 1996 human mature miRNAs, pre-miRNAs and

snoRNAs, respectively. Labeled RNA was hybridized to the array, washed, and stained in a GeneChip Fluidics Station 450. Then, they were scanned using a GeneChip Scanner 7G (Affymetrix, Santa Clara, CA, USA). Microarray data analysis was carried out using Transcriptome Analysis Console v4.0 (TAC) software (Affymetrix, Santa Clara, CA, USA). This analysis applied the robust multi-array average (RMA) and the detection above background (DABG) algorithm, specifically tailored for human probe sets, to background correction, quantile normalization, detection, and summarization. The batch effect observed was removed using the batch effect module of the TAC software.

Finally, a differential expression analysis between the groups was performed using TAC Software to obtain the DE sncRNAs. Briefly, the software implements the limma differential expression analysis (Bioconductor package 3.19). A p -value < 0.05 and an absolute fold-change (FC) value $\geq |2|$ were considered as DE sncRNAs. The following established comparisons were considered:

- (1) Old vs. young;
- (2) Centenarian vs. old;
- (3) Centenarian vs. young.

Venn diagrams were built using the Venny web tool "<https://bioinfogp.cnb.csic.es/tools/venny/index.html> (accessed in 25 July 2024)".

As another approach, a Pearson correlation analysis between the expression of sncRNAs and age was conducted. A Pearson correlation coefficient of $r > |0.6|$ and a p -value < 0.01 were the filtering criteria.

4.3. Bioinformatic In Silico Analysis

The in silico analysis was conducted using the mRNA targets of the age-regulated miRNAs registered in the miRTarBase database [58]. Age-regulated miRNAs were considered those identified by differential expression and correlation analysis, and only with a miRbase identifier of a mature miRNA (excluding identifiers related to precursor miRNA and others). In addition, we used transcriptomic mRNA data available from the same hippocampal samples previously reported [17] to obtain mRNA targets that were differentially expressed in these samples, which we refer to as experimentally validated targets. With this approach, we created experimentally validated mRNA-miRNA networks in our samples using Cytoscape v3.10.1. Then, mRNA-miRNA interactions exhibiting opposite regulation were finally plotted. miRNA-mRNA opposite regulation means that when the miRNA is upregulated, the mRNA target is downregulated and vice versa. Finally, to describe the function of the mentioned mRNA targeted by the miRNAs, clusterProfiler (v4.12.2) of Bioconductor r package (v3.19) was used for the gene ontology analysis, along with human annotation database org.Hs.eg.db (v3.19.1, accessed on 30 July 2024), available through Bioconductor. Benjamini–Hochberg multiple testing FDR correction was carried out, considering the FDR value < 0.05 as a significant threshold.

4.4. RT-qPCR Candidates Validation

For the validation of miRNA candidates, total RNA was reverse transcribed (RT) into cDNA using a miScript II RT kit (Qiagen, Hilden, Germany). The concentration and purity of RNA were determined at 260/280 nm using a NanoDrop-ND 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). To quantify miRNA expression by quantitative polymerase chain reaction (qPCR), we used miScript Primer Assays and miScript SYBR Green PCR kit (Qiagen, Germany), using 10 ng cDNA following the manufacturer's protocol. The median of hsa-let-7b-5p and hsa-miR-191-5p was used as reference genes for normalization purposes.

4.5. Statistical Analysis

Results of the validation cohort were expressed as ΔCq values considering the difference of Ct values between the miRNA candidate and the median of reference genes. Statistical significance was determined using a parametric ordinary one-way ANOVA

test and Tukey's post hoc test. Pearson's correlation coefficient test was used to determine the correlation between continuous variables. Both were performed by R software v4.4.1 "<http://cran.r-project.org>", and differences with $p < 0.05$ were considered statistically significant.

5. Conclusions

In conclusion, our findings identified a set of hippocampal miRNAs significantly deregulated with aging, highlighting their crucial role as transcription regulators. Moreover, the potential of miRNAs as non-invasive biomarkers for aging, longevity, and age-related conditions, such as frailty and neurodegenerative diseases, warrants further exploration, particularly regarding their ability to reflect tissue expression patterns when circulating freely or encapsulated in EVs.

Supplementary Materials: The supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/ijms252312872/s1>.

Author Contributions: Study conceptualization and design: A.A., A.M., M.M.-C. and D.O.; Sample collection: A.A., M.A.-I. and A.M.; Experiments: A.A., S.G.S.I., A.I.-L. and M.M.-C.; Bioinformatics analysis: A.A., M.M.-C. and D.O.; Analysis and interpretation of results: A.A., R.D.C.B.-M., M.M.-C. and D.O.; Manuscript preparation: R.D.C.B.-M.; Review and editing: R.D.C.B.-M., A.I.-L., A.M., M.M.-C. and D.O. All authors have read and agreed to the published version of the manuscript.

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the project has been partially covered by Projects from the Health Department of the Basque Country (2000111029 and 2023111072). A.A. is supported by a postdoctoral research fellowship from the Basque Government (POS_2020_1_0008). R.D.C.B.-M. is funded by the ECTRIMS Postdoctoral Research Fellowship Programme. A.I.-L. is supported by the P-FIS predoctoral grant (FI21/00054) from the Carlos III Health Research Institute (ISCIII). The other authors received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Clinical Research Ethics Committee of The Donostia University Hospital (protocol AMF-EGM-2016-01).

Informed Consent Statement: Informed consent was obtained from the families of the subjects involved in the study.

Data Availability Statement: The obtained data discussed in this work have been deposited in NCBI's Gene Expression Omnibus and are accessible in GSE275442.

Acknowledgments: The authors thank all the donors and families who participated in the study. We also thank the Genomic Platform of the Biogipuzkoa Health Research Institute for its technical assistance. In addition, thank you to all the workers from the Basque Biobank (BIOEF, Donostia University Hospital).

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

References

1. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. *Cell* **2013**, *153*, 1194–1217. [[CrossRef](#)] [[PubMed](#)]
2. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. Hallmarks of Aging: An Expanding Universe. *Cell* **2023**, *186*, 243–278. [[CrossRef](#)] [[PubMed](#)]
3. Tartiere, A.G.; Freije, J.M.P.; López-Otín, C. The Hallmarks of Aging as a Conceptual Framework for Health and Longevity Research. *Front. Aging Res.* **2024**, *5*, 1334261. [[CrossRef](#)]
4. Rivero-Segura, N.A.; Bello-Chavolla, O.Y.; Barrera-Vázquez, O.S.; Gutierrez-Robledo, L.M.; Gomez-Verjan, J.C. Promising Biomarkers of Human Aging: In Search of a Multi-Omics Panel to Understand the Aging Process from a Multidimensional Perspective. *Ageing Res. Rev.* **2020**, *64*, 101164. [[CrossRef](#)] [[PubMed](#)]
5. Muñoz-Culla, M.; Irizar, H.; Gorostidi, A.; Alberro, A.; Osorio-Querejeta, I.; Ruiz-Martínez, J.; Olascoaga, J.; López de Munain, A.; Otaegui, D. Progressive Changes in Non-Coding RNA Profile in Leucocytes with Age. *Aging* **2017**, *9*, 1202–1218. [[CrossRef](#)]

6. Morris, B.J.; Willcox, B.J.; Donlon, T.A. Genetic and Epigenetic Regulation of Human Aging and Longevity. *Biochim. Biophys. Acta Mol. Basis Dis.* **2019**, *1865*, 1718–1744. [[CrossRef](#)]
7. Marttila, S.; Chatsirisupachai, K.; Palmer, D.; de Magalhães, J.P. Ageing-Associated Changes in the Expression of LncRNAs in Human Tissues Reflect a Transcriptional Modulation in Ageing Pathways. *Mech. Ageing Dev.* **2020**, *185*, 111177. [[CrossRef](#)]
8. Wang, J.; Zhang, H.; Wang, C.; Fu, L.; Wang, Q.; Li, S.; Cong, B. Forensic Age Estimation from Human Blood Using Age-Related MicroRNAs and Circular RNAs Markers. *Front. Genet.* **2022**, *13*, 1031806. [[CrossRef](#)]
9. Niu, Y.Y.; Zhong, J.F.; Wen, H.Y.; Yan, H.Y.; Diao, Z.Q.; Li, J.X.; Bai, X.R.; Qiu, J.M.; Xu, Z.T.; Chen, L.H.; et al. Association of Combined Healthy Lifestyle Factors With Incident Dementia in Participants With and Without Multimorbidity: A Large Population-Based Prospective Cohort Study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2024**, *79*, glae034. [[CrossRef](#)]
10. Carthew, R.W.; Sontheimer, E.J. Origins and Mechanisms of MiRNAs and SiRNAs. *Cell* **2009**, *136*, 642–655. [[CrossRef](#)]
11. O'Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front. Endocrinol.* **2018**, *9*, 402. [[CrossRef](#)] [[PubMed](#)]
12. López-Otín, C.; Maier, A.B.; Kroemer, G. Gerogenes and Gerosuppression: The Pillars of Precision Geromedicine. *Cell Res.* **2024**, *34*, 463–466. [[CrossRef](#)] [[PubMed](#)]
13. Persengiev, S.P.; Kondova, I.I.; Bontrop, R.E. The Impact of MicroRNAs on Brain Aging and Neurodegeneration. *Curr. Gerontol. Geriatr. Res.* **2012**, *2012*, 359369. [[CrossRef](#)] [[PubMed](#)]
14. Williams, J.; Smith, F.; Kumar, S.; Vijayan, M.; Reddy, P.H. Are MicroRNAs True Sensors of Ageing and Cellular Senescence? *Ageing Res. Rev.* **2017**, *35*, 350–363. [[CrossRef](#)] [[PubMed](#)]
15. Harries, L.W. MicroRNAs as Mediators of the Ageing Process. *Genes* **2014**, *5*, 656–670. [[CrossRef](#)]
16. Smith-Vikos, T.; Slack, F.J. MicroRNAs and Their Roles in Aging. *J. Cell Sci.* **2012**, *125*, 7–17. [[CrossRef](#)]
17. Saenz-Antoñanzas, A.; Muñoz-Culla, M.; Rigo, P.; Ruiz-Barreiro, L.; Moreno-Valladares, M.; Alberro, A.; Cruces-Salguero, S.; Arroyo-Izaga, M.; Arranz, A.M.; Otaegui, D.; et al. Centenarian Hippocampus Displays High Levels of Astrocytic Metallothioneins. *Aging Cell* **2024**, *23*, e14201. [[CrossRef](#)]
18. Kumar Dev, P.; Gray, A.J.; Scott-Hamilton, J.; Hagstrom, A.D.; Murphy, A.; Denham, J. Co-Expression Analysis Identifies Networks of MiRNAs Implicated in Biological Ageing and Modulated by Short-Term Interval Training. *Mech. Ageing Dev.* **2021**, *199*, 111552. [[CrossRef](#)]
19. Lu, J.; Li, S.; Li, X.; Zhao, W.; Duan, X.; Gu, X.; Xu, J.; Yu, B.; Sigal, L.J.; Dong, Z.; et al. Declined MiR-181a-5p Expression Is Associated with Impaired Natural Killer Cell Development and Function with Aging. *Aging Cell* **2021**, *20*, e13353. [[CrossRef](#)]
20. Massaro, F.; Corrillon, F.; Stamatopoulos, B.; Dubois, N.; Ruer, A.; Meuleman, N.; Bron, D.; Lagneaux, L. Age-Related Changes in Human Bone Marrow Mesenchymal Stromal Cells: Morphology, Gene Expression Profile, Immunomodulatory Activity and MiRNA Expression. *Front. Immunol.* **2023**, *14*, 1267550. [[CrossRef](#)]
21. Qi, L.; Li, X.; Liu, S.M.; Jiao, D.L.; Hu, D.; Ju, X.Y.; Zhao, S.Y.; Si, S.H.; Hu, L.; Li, G.N.; et al. Identification of a Hippocampal LncRNA-Regulating Network in a Natural Aging Rat Model. *BMC Neurosci.* **2022**, *23*, 56. [[CrossRef](#)] [[PubMed](#)]
22. Krarup, J.; Araya, L.; Álvarez, F.; Bórquez, D.A.; Urrutia, P.J. A Brain Anti-Senescence Transcriptional Program Triggered by Hypothalamic-Derived Exosomal MicroRNAs. *Int. J. Mol. Sci.* **2024**, *25*, 5467. [[CrossRef](#)] [[PubMed](#)]
23. Moreno-Jiménez, E.P.; Flor-García, M.; Terreros-Roncal, J.; Rábano, A.; Cafini, F.; Pallas-Bazarra, N.; Ávila, J.; Llorens-Martín, M. Adult Hippocampal Neurogenesis Is Abundant in Neurologically Healthy Subjects and Drops Sharply in Patients with Alzheimer's Disease. *Nat. Med.* **2019**, *25*, 554–560. [[CrossRef](#)] [[PubMed](#)]
24. Toda, T.; Parylak, S.L.; Linker, S.B.; Gage, F.H. The Role of Adult Hippocampal Neurogenesis in Brain Health and Disease. *Mol. Psychiatry* **2019**, *24*, 67–87. [[CrossRef](#)] [[PubMed](#)]
25. Rahman, M.R.; Petralia, M.C.; Ciurleo, R.; Bramanti, A.; Fagone, P.; Shahjaman, M.; Wu, L.; Sun, Y.; Turanli, B.; Arga, K.Y.; et al. Comprehensive Analysis of RNA-Seq Gene Expression Profiling of Brain Transcriptomes Reveals Novel Genes, Regulators, and Pathways in Autism Spectrum Disorder. *Brain Sci.* **2020**, *10*, 747. [[CrossRef](#)]
26. Ren, F.-J.; Yao, Y.; Cai, X.-Y.; Fang, G.-Y. Emerging Role of MiR-192-5p in Human Diseases. *Front. Pharmacol.* **2021**, *12*, 614068. [[CrossRef](#)]
27. Zhao, B.; Jiang, X. Hsa-MiR-518-5p/Hsa-MiR-3135b Regulates the REL/SOD2 Pathway in Ischemic Cerebral Infarction. *Front. Neurol.* **2022**, *13*, 852013. [[CrossRef](#)]
28. Shi, J.; Ren, Y.; Liu, Y.; Cheng, Y.; Liu, Y. Circulating MiR-3135b and MiR-107 Are Potential Biomarkers for Severe Hypertension. *J. Hum. Hypertens.* **2021**, *35*, 343–350. [[CrossRef](#)]
29. Chen, F.; Yang, J.; Li, Y.; Wang, H. Circulating MicroRNAs as Novel Biomarkers for Heart Failure. *Hellenic J. Cardiol.* **2018**, *59*, 209–214. [[CrossRef](#)]
30. Ramaswamy, P.; Athira, S.V.; Misra, P.; Chauhan, V.S.; Adhvaryu, A.; Gupta, A.; Ankita, G.; Sibin, M.K. Circulating MicroRNA Profiling Identifies MicroRNAs Linked to Prediabetes Associated with Alcohol Dependence Syndrome. *Alcohol* **2024**, *42*, 109–118. [[CrossRef](#)]
31. Wang, F.; Li, Z.; Zhao, M.; Ye, W.; Wu, H.; Liao, Q.; Bu, S.; Zhang, Y. Circulating MiRNAs MiR-574-5p and MiR-3135b Are Potential Metabolic Regulators for Serum Lipids and Blood Glucose in Gestational Diabetes Mellitus. *Gynecol. Endocrinol.* **2021**, *37*, 665–671. [[CrossRef](#)] [[PubMed](#)]

32. Wagner, V.; Kern, F.; Hahn, O.; Schaum, N.; Ludwig, N.; Fehlmann, T.; Engel, A.; Henn, D.; Rishik, S.; Isakova, A.; et al. Characterizing Expression Changes in Noncoding RNAs during Aging and Heterochronic Parabiosis across Mouse Tissues. *Nat. Biotechnol.* **2024**, *42*, 109–118. [[CrossRef](#)] [[PubMed](#)]
33. Demirel, G.; Tanoglu, E.G.; Ashiyuksek, H. Evaluation of MicroRNA Let-7b-3p Expression Levels in Methamphetamine Abuse. *Rev. Assoc. Med. Bras. (1992)* **2023**, *69*, e20221391. [[CrossRef](#)] [[PubMed](#)]
34. Mills, J.D.; van Vliet, E.A.; Chen, B.J.; Janitz, M.; Anink, J.J.; Baayen, J.C.; Idema, S.; Devore, S.; Friedman, D.; Diehl, B.; et al. Coding and Non-Coding Transcriptome of Mesial Temporal Lobe Epilepsy: Critical Role of Small Non-Coding RNAs. *Neurobiol. Dis.* **2020**, *134*, 104612. [[CrossRef](#)] [[PubMed](#)]
35. Moreau, M.P.; Bruse, S.E.; Jornsten, R.; Liu, Y.; Brzustowicz, L.M. Chronological Changes in MicroRNA Expression in the Developing Human Brain. *PLoS ONE* **2013**, *8*, e60480. [[CrossRef](#)]
36. Tatara, Y.; Yamazaki, H.; Katsuoka, F.; Chiba, M.; Saigusa, D.; Kasai, S.; Nakamura, T.; Inoue, J.; Aoki, Y.; Shoji, M.; et al. Multiomics and Artificial Intelligence Enabled Peripheral Blood-Based Prediction of Amnesic Mild Cognitive Impairment. *Curr. Res. Transl. Med.* **2023**, *71*, 103367. [[CrossRef](#)]
37. Pathan, M.; Fonseka, P.; Chitti, S.V.; Kang, T.; Sanwlani, R.; Van Deun, J.; Hendrix, A.; Mathivanan, S. Vesiclepedia 2019: A Compendium of RNA, Proteins, Lipids and Metabolites in Extracellular Vesicles. *Nucleic Acids Res.* **2019**, *47*, D516–D519. [[CrossRef](#)]
38. Zhou, X.; Chen, X.; Hong, T.; Zhang, M.; Cai, Y.; Cui, L. TTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive Impairment. *Cell. Mol. Neurobiol.* **2021**, *42*, 1659–1669. [[CrossRef](#)]
39. Mor, M.; Nardone, S.; Sams, D.S.; Elliott, E. Hypomethylation of MiR-142 Promoter and Upregulation of MicroRNAs That Target the Oxytocin Receptor Gene in the Autism Prefrontal Cortex. *Mol. Autism* **2015**, *6*, 46. [[CrossRef](#)]
40. Huang, Z.X.; Chen, Y.; Guo, H.R.; Chen, G.F. Systematic Review and Bioinformatic Analysis of MicroRNA Expression in Autism Spectrum Disorder Identifies Pathways Associated With Cancer, Metabolism, Cell Signaling, and Cell Adhesion. *Front. Psychiatry* **2021**, *12*, 630876. [[CrossRef](#)]
41. Wan, Y.; Liu, Y.; Wang, X.; Wu, J.; Liu, K.; Zhou, J.; Liu, L.; Zhang, C. Identification of Differential MicroRNAs in Cerebrospinal Fluid and Serum of Patients with Major Depressive Disorder. *PLoS ONE* **2015**, *10*, e0121975. [[CrossRef](#)] [[PubMed](#)]
42. Prabhakar, P.; Chandra, S.R.; Christopher, R. Circulating MicroRNAs as Potential Biomarkers for the Identification of Vascular Dementia Due to Cerebral Small Vessel Disease. *Age Ageing* **2017**, *46*, 861–864. [[CrossRef](#)] [[PubMed](#)]
43. Ragusa, M.; Santagati, M.; Mirabella, F.; Lauretta, G.; Ciriogliaro, M.; Brex, D.; Barbagallo, C.; Domini, C.N.; Gulisano, M.; Barone, R.; et al. Potential Associations Among Alteration of Salivary MiRNAs, Saliva Microbiome Structure, and Cognitive Impairments in Autistic Children. *Int. J. Mol. Sci.* **2020**, *21*, 6203. [[CrossRef](#)] [[PubMed](#)]
44. Agostini, S.; Mancuso, R.; Costa, A.S.; Guerini, F.R.; Trecate, F.; Miglioli, R.; Menna, E.; Arosio, B.; Clerici, M. Sarcopenia Associates with SNAP-25 SNPs and a MiRNAs Profile Which Is Modulated by Structured Rehabilitation Treatment. *J. Transl. Med.* **2021**, *19*, 315. [[CrossRef](#)] [[PubMed](#)]
45. McKeever, P.M.; Schneider, R.; Taghdiri, F.; Weichert, A.; Multani, N.; Brown, R.A.; Boxer, A.L.; Karydas, A.; Miller, B.; Robertson, J.; et al. MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. *Mol. Neurobiol.* **2018**, *55*, 8826. [[CrossRef](#)]
46. Wang, L.; Zhen, H.; Sun, Y.; Rong, S.; Li, B.; Song, Z.; Liu, Z.; Li, Z.; Ding, J.; Yang, H.; et al. Plasma Exo-MiRNAs Correlated with AD-Related Factors of Chinese Individuals Involved in A β Accumulation and Cognition Decline. *Mol. Neurobiol.* **2022**, *59*, 6790–6804. [[CrossRef](#)]
47. Gámez-Valero, A.; Campdelacreu, J.; Vilas, D.; Ispuerto, L.; Reñé, R.; Álvarez, R.; Armengol, M.P.; Borràs, F.E.; Beyer, K. Exploratory Study on MicroRNA Profiles from Plasma-Derived Extracellular Vesicles in Alzheimer's Disease and Dementia with Lewy Bodies. *Transl. Neurodegener.* **2019**, *8*, 31. [[CrossRef](#)]
48. Seršić, L.V.; Alić, V.K.; Biberić, M.; Zrna, S.; Jagoić, T.; Tarčuković, J.; Grabušić, K. Real-Time PCR Quantification of 87 MiRNAs from Cerebrospinal Fluid: MiRNA Dynamics and Association with Extracellular Vesicles after Severe Traumatic Brain Injury. *Int. J. Mol. Sci.* **2023**, *24*, 4751. [[CrossRef](#)]
49. Feng, H.; Hu, P.; Chen, Y.; Sun, H.; Cai, J.; He, X.; Cao, Q.; Yin, M.; Zhang, Y.; Li, Q.; et al. Decreased MiR-451a in Cerebrospinal Fluid, a Marker for Both Cognitive Impairment and Depressive Symptoms in Alzheimer's Disease. *Theranostics* **2023**, *13*, 3021–3040. [[CrossRef](#)]
50. Agostini, S.; Mancuso, R.; Citterio, L.A.; Mihali, G.A.; Arosio, B.; Clerici, M. Evaluation of Serum MiRNAs Expression in Frail and Robust Subjects Undergoing Multicomponent Exercise Protocol (VIVIFRAIL). *J. Transl. Med.* **2023**, *21*, 67. [[CrossRef](#)]
51. Trattng, C.; Üçal, M.; Tam-Amersdorfer, C.; Bucko, A.; Zefferer, U.; Grünbacher, G.; Absenger-Novak, M.; Öhlinger, K.A.; Kraitsy, K.; Hamberger, D.; et al. MicroRNA-451a Overexpression Induces Accelerated Neuronal Differentiation of Ntera2/D1 Cells and Ablation Affects Neurogenesis in MicroRNA-451a^{-/-} Mice. *PLoS ONE* **2018**, *13*, e0207575. [[CrossRef](#)] [[PubMed](#)]
52. Lee, J.K.; Oh, S.J.; Gim, J.A.; Shin, O.S. MiR-10a, MiR-30c, and MiR-451a Encapsulated in Small Extracellular Vesicles Are Prosenescence Factors in Human Dermal Fibroblasts. *J. Invest. Dermatol.* **2022**, *142*, 2570–2579.e6. [[CrossRef](#)] [[PubMed](#)]
53. Chenery, A.; Burrows, K.; Antignano, F.; Underhill, T.M.; Petkovich, M.; Zaph, C. The Retinoic Acid-Metabolizing Enzyme Cyp26b1 Regulates CD4 T Cell Differentiation and Function. *PLoS ONE* **2013**, *8*, e72308. [[CrossRef](#)] [[PubMed](#)]
54. Spoorendonk, K.M.; Peterson-Maduro, J.; Renn, J.; Trowe, T.; Kranenbarg, S.; Winkler, C.; Schulte-Merker, S. Retinoic Acid and Cyp26b1 Are Critical Regulators of Osteogenesis in the Axial Skeleton. *Development* **2008**, *135*, 3765–3774. [[CrossRef](#)]

55. Laue, K.; Jänicke, M.; Plaster, N.; Sonntag, C.; Hammerschmidt, M. Restriction of Retinoic Acid Activity by Cyp26b1 Is Required for Proper Timing and Patterning of Osteogenesis during Zebrafish Development. *Development* **2008**, *135*, 3775–3787. [[CrossRef](#)]
56. Snyder, J.M.; Zhong, G.; Hogarth, C.; Huang, W.; Topping, T.; LaFrance, J.; Palau, L.; Czuba, L.C.; Griswold, M.; Ghiaur, G.; et al. Knockout of Cyp26a1 and Cyp26b1 during Postnatal Life Causes Reduced Lifespan, Dermatitis, Splenomegaly, and Systemic Inflammation in Mice. *FASEB J.* **2020**, *34*, 15788–15804. [[CrossRef](#)]
57. Vogel, J.W.; La Joie, R.; Grothe, M.J.; Diaz-Papkovich, A.; Doyle, A.; Vachon-Preseau, E.; Lepage, C.; Vos de Wael, R.; Thomas, R.A.; Iturria-Medina, Y.; et al. A Molecular Gradient along the Longitudinal Axis of the Human Hippocampus Informs Large-Scale Behavioral Systems. *Nat. Commun.* **2020**, *11*, 960. [[CrossRef](#)]
58. Huang, H.Y.; Lin, Y.C.D.; Cui, S.; Huang, Y.; Tang, Y.; Xu, J.; Bao, J.; Li, Y.; Wen, J.; Zuo, H.; et al. MiRTarBase Update 2022: An Informative Resource for Experimentally Validated MiRNA–Target Interactions. *Nucleic Acids Res.* **2022**, *50*, D222–D230. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.